SU BioMedicine and Diapharm collaborate to register and market high quality Chinese medicines in Europe
New venture will support the unmet medical/societal need for cure and care products for personalised health strategies
SU BioMedicine and Diapharm have signed a strategic collaboration agreement to bring Chinese medicines into the EU market.
Both companies have been involved in the marketing authorisation process for Traditional Chinese Medicines (TCM) for some time and, together, they will become the leading resource for the registration and distribution of TCM in Europe.
‘Dedicated to improving healthcare, SU BioMedicine is proud to partner with Diapharm to accelerate the introduction of high quality cure and care products into the European market,’ said Jan van der Greef, CEO of SU BioMedicine.
‘Our strategic partnership will bring new preventive and personalised medicines to patients in Europe. At the same time, it creates added value to our long-term expertise in herbal medicine registration,’ said Ralf Sibbing, General Manager of Diapharm.
SU BioMedicine was the first company to register a Chinese medicine in the EU that complied with the Traditional Herbal Medicinal Products (THMP) guidelines. Furthermore, SU BioMedicine’s unique knowledge in systems biology facilitates the translation of Chinese interventional concepts into Western scientific principles.
Diapharm boasts a history of expertise in the field of herbal medicines in Europe, from regulatory affairs to quality management, and has an extensive network of partners to establish marketing and sales outlets in the various EU member states. Diapharm's Shanghai (China) office advises and assists Chinese pharmaceutical companies to enter the European marketplace.
